Studies | Phase Ib/II for CLL/SLL | Phase Ib/II for CLL patients (N=116) [26] | Ibrutinib | Ibrutinib | ||
---|---|---|---|---|---|---|
+ | + | |||||
 |  |  |  |  | Rituximab | Ofatumumab |
 | (High risk refractory/relapsed) | Treatment naïve patients >65 years old | Relapsed/refractory | High risk relapsed/refractory | (Relapsed/refractory CLL) | (Relapsed/refractory CLL) |
 | [N=85] [24] |  |  |  | [N=40] [40] | [N=40] [41] |
ORR | 71% | 71% (CR=10%, PR=61%) | 67 % (CR=3%, PR=64%) | 50% (PR=50%, CR=0%) | 85% | 100% |